Neurocrine submits valbenazine NDA

Neurocrine Biosciences Inc. (NASDAQ:NBIX) submitted an NDA to FDA for valbenazine ( MT-5199, NBI-98854) to treat tardive dyskinesia.

Last year, the selective vesicular monoamine transporter 2 (VMAT2; SLC18A2) inhibitor met the primary endpoint in a Phase III study in the indication (see BioCentury Extra, Oct. 8, 2015). ...